Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Seniors With IBD

Author:

Bernstein Charles N12ORCID,Singh Harminder12,Murthy Sanjay K3,Nguyen Geoffrey C4ORCID,Benchimol Eric I5678ORCID,Bitton Alain9,Kuenzig M Ellen56ORCID,Huang James Guoxian5,Jones Jennifer L10,Lee Kate11,Targownik Laura E12,Windsor Joseph W1314ORCID,Mukhtar Mariam S15,Tandon Parul12ORCID,Kaplan Gilaad G1314ORCID

Affiliation:

1. Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada

2. IBD Clinical and Research Centre, University of Manitoba, Winnipeg, Manitoba, Canada

3. Department of Medicine, The Ottawa Hospital IBD Centre, University of Ottawa, Ottawa, Ontario, Canada

4. Mount Sinai Hospital Inflammatory Bowel Disease Centre, University of Toronto, Toronto, Ontario, Canada

5. SickKids Inflammatory Bowel Disease Centre, Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, Toronto, Ontario, Canada

6. Child Health Evaluative Sciences, SickKids Research Institute, Toronto, Ontario, Canada

7. ICES, Toronto, Ontario, Canada

8. Department of Paediatrics and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada

9. Department of Medicine, McGill University Health Centre, McGill University, Montreal, Quebec, Canada

10. Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada

11. Crohn’s and Colitis Canada, Toronto, Ontario, Canada

12. Division of Gastroenterology and Hepatology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada

13. Department of Medicine, University of Calgary, Calgary, Alberta, Canada

14. Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada

15. Department of Internal Medicine, King Abdulaziz University Hospital, Jeddah, Saudi Arabia

Abstract

Abstract The risk of hospitalization and death from Coronavirus disease-19 (COVID-19) increases with age. The extreme elderly have been particularly vulnerable, with those above the age of 80 having a case-fatality rate as high as 15%. Aging of the immune system can lead to impaired inflammatory responses where eradication of an organism such as Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV2) is inadequate but is exaggerated in such a way as to enhance pneumonia and acute respiratory distress syndrome. Frailty and comorbidity are both more common in the elderly, and these can enhance the morbidity and mortality from COVID-19. Studies from Northern California and Italy suggest that elderly persons with inflammatory bowel disease (IBD) were more likely to acquire SARS-CoV-2 infection than youths with IBD. While the specific impact of age-related comorbidity is less well established among people with IBD who acquire COVID-19, data from the Surveillance Epidemiology of Coronavirus Under Research Exclusion (SECURE-IBD) database reported that having two or more chronic illnesses was independently associated with developing severe COVID-19 among people with IBD. Despite having exaggerated auto-inflammatory responses, people with IBD do not appear to have an overall increased risk of developing severe COVID-19 than the general population. However, whether seniors with IBD do worse once they acquire COVID-19 compared with seniors without IBD is not known. The advent of telehealth care has posed an information technology challenge for many seniors with and without IBD. Most persons with IBD have expressed satisfaction with virtual IBD health care (phone or video-based visits). While the elderly may have less robust immune responses to vaccinations, learning from experiences with other vaccination programs, especially influenza, have shown that vaccinating seniors decreases both morbidity and mortality and, in turn, healthcare resources.

Funder

Crohn’s and Colitis Canada

Canadian Institutes of Health Research

Pfizer

AbbVie Corporation

Takeda Canada Inc.

Publisher

Oxford University Press (OUP)

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3